Reaction
Medullary Thyroid Cancer reporting signals
As of the last recalculation, Medullary Thyroid Cancer appears in 332 FAERS reports alongside 5 co-occurring drug terms. The strongest observed disproportionality signal is ORAL SEMAGLUTIDE (PRR 63.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Oral Semaglutide | 61 | 63.6 | 63.6 |
| Liraglutide | 41 | 59.2 | 59.3 |
| Exenatide | 22 | 28.0 | 28.0 |
| Dulaglutide | 21 | 15.8 | 15.8 |
| Tirzepatide | 34 | 14.6 | 14.6 |